Tobramycin sulfate

Tobramycin sulfate
Product Description

Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic active against Gram-negative bacteria including most Enterobacteriaceae, Pseudomonas aeruginosa and a few Gram-positive bacteria such as Staphylococcus aureus.

Indication: Used in the treatment of septicemia (bloodstream infection), infections of the skin, bone, lower respiratory tract, central nervous system, intra-abdominal and complicated recurrent urinary tract infections.

Application: Administered systemically by intramuscular injections or intravenous infusions. Can be mixed with bone cement.

Shelf-life: 3 years

Storage conditions: Below 25°C (77°F)

For further information contact us at [email protected] 

or access our product sheet online https://xellia.com/products/Tobramycin%20Sulfate/

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer

More Products from Xellia Pharmaceuticals ApS (21)

  • Bacitracin

    Product Bacitracin

    Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

    Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the...
  • Bacitracin zinc

    Product Bacitracin zinc

    Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

    Indication: Used in the treatm...
  • Colistimethate sodium (CMS)

    Product Colistimethate sodium (CMS)

    Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

    I...
  • Daptomycin

    Product Daptomycin

    Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol...
  • Gramicidin

    Product Gramicidin

    Gramicidin is a mixture of linear polypeptides active against a variety of Gram-positive bacteria.

    Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria, such...
  • Polymyxin B sulfate

    Product Polymyxin B sulfate

    Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other Gram-negative bacteria.

    Indication: Used in the treatment of acute urinary, meningeal or blood stream infections due to Pseudomonas aeruginosa and other ...
  • Tyrothricin

    Product Tyrothricin

    Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.

    ...
  • Vancomycin hydrochloride (manufactured in Budapest, Hungary)

    Product Vancomycin hydrochloride (manufactured in Budapest, Hungary)

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, en...
  • Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)

    Product Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...
  • Vancomycin hydrochloride (manufactured in Taizhou, China)

    Product Vancomycin hydrochloride (manufactured in Taizhou, China)

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...
  • Bacitracin vials

    Product Bacitracin vials

    Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.

    Indi...
  • Colistimethate sodium lyophilized vials

    Product Colistimethate sodium lyophilized vials

    Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

    Indication:&nbs...

Xellia Pharmaceuticals ApS resources (2)

  • News Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.
  • Technical Data Xellia Corporate Introduction

    Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.